Ascendis Pharma
Manufacturing · Denmark · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Tuborg Blvd 12, Hellerup, Region Hovedst...Phone Number
+45 70222244Website
www.ascendispharma.comRevenue
$986.3 MillionStock Symbol
ASNDIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Ascendis Pharma
Ascendis Pharma A/S is a global biopharmaceutical company committed to developing innovative therapies that address unmet medical needs and improve patient outcomes. The company leverages its proprietary TransCon® technology platform to develop new, potentially best-in-class treatments with improved safety, efficacy, tolerability, and convenience. Its pipeline includes therapies for rare endocrinology diseases and other serious conditions, with commercial products and candidates advancing in clinical development worldwide. Headquartered in Copenhagen, Denmark, Ascendis Pharma operates internationally, with additional facilities and offices in Europe and the United States.Explore more
Ascendis Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ascendis Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Ascendis Pharma recently announced quarterly report
Check if Ascendis Pharma has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Ascendis Pharma had a recent Job posting/layoffs
Check out if Ascendis Pharma is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Ascendis Pharma launches new products
Funding: Get notified immidiatlly once Ascendis Pharma has new funding data
Ascendis Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Ascendis Pharma
Recommended Actions
Reach out to Masked Content who joined Ascendis Pharma as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Ascendis Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ascendis Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ascendis Pharma.
Ascendis Pharma financials insights
Gather financial insights about Ascendis Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Stock Offering
$108M
Ascendis Pharma Tech Stack
A closer look at the technologies used by Ascendis Pharma
Most Recent Scoops
Open Position
Open Position
Person-Based
Earnings, Finance
Earnings
Ascendis Pharma has reported YUVIWEL revenue of EUR 8 million for Q2 2026, its first quarter on the US market following commercial launch, reflecting strong demand and rapid conversion to paid therapy.
Earnings, Finance
Project
Clinical Operations
Ascendis Pharma News & Media
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
COPENHAGEN, Denmark, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time in New York, New York.Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress of the European Society for Paediatric Endocrinology (ESPE) being held September 8-10, 2026, in Marseille, France. Updates will include a podium presentation of the first sentinel cohort data from the pivotal reACHin Trial of TransCon CNP (navepegritide) in infants with achondropAscendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)
COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with BioMarin Pharmaceutical Inc. (“BioMarin”) related to the sale of YUVIWEL® and navepegritide-related products. The binding term sheet provides the terms and conditions upon which the companies agree to resolve all litigation and disputes between the companies.Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026
COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its participation at ISDS 2026, the annual meeting of the International Skeletal Dysplasia Society being held in Toronto, Canada, from August 26-29, 2026, will include an oral presentation of Week 104 data from its pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. The presentation will be given by Carlos Bacino, M.D., FACMG, Professor of
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ascendis Pharma
Sign Up For FreeTo access detailed company insights
Ascendis Pharma A/S is a global biopharmaceutical company committed to developing innovative therapies that address unmet medical needs and improve patient outcomes. The company leverages its proprietary TransCon® technology platform to develop new, potentially best-in-class treatments with improved safety, efficacy, tolerability, and convenience.... Read More
